|
|
| Contact for Additional Information |
Report Adverse Events |
| Bayer Medical Communications |
Bayer Adverse Events Reporting |
| Phone |
1-888-842-2937 |
| Fax |
1-973-305-3570 |
| eMail |
mps.bayer@bayer.com |
| Mail |
Bayer Medical Communications
6 West Belt
Wayne, NJ 07470 USA |
|
| eMail |
DrugSafety.GPV.US@bayer.com |
| Fax |
1-973-709-2185 |
| Mail |
Global Pharmacovigilance - USA
Bayer HealthCare Pharmaceuticals Inc.
PO Box 1000
Montville, NJ 07045-1000 USA |
|
|
|
About Trasylol
Trasylol® is indicated for prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion.
Trasylol® administration may cause fatal anaphylactic or anaphylactoid reactions.
Fatal reactions have occurred with an initial (test) dose as well as with any of the components of the dose regimen.
Fatal reactions have also occurred in situations where the initial (test) dose was tolerated. The risk for anaphylactic or
anaphylactoid reactions is increased among patients with prior aprotinin exposure and a history of any prior aprotinin
exposure must be sought prior to Trasylol® administration. The risk for a fatal reaction appears to be greater upon
re-exposure within 12 months of the most recent prior aprotinin exposure. Trasylol® should be administered only in operative
settings where cardio-pulmonary bypass can be rapidly initiated. The benefit of Trasylol® to patients undergoing primary CABG
surgery should be weighed against the risk of anaphylaxis associated with any subsequent exposure to aprotinin.
(See CONTRAINDICATIONS, WARNINGS and PRECAUTIONS in the prescribing information.) |
|
Safety Considerations
Trasylol is contraindicated in patients with a known or suspected aprotinin exposure during the last 12 months. Aprotinin may also be a component of some fibrin sealant products.
- In clinical studies, hypersensitivity and anaphylactic reactions were rare (<0.1%) in patients with no prior exposure to Trasylol.
Trasylol administration increases the risk for renal dysfunction and may increase the need for dialysis in the perioperative period.
- This risk may be especially increased for patients with pre-existing renal impairment or those who receive aminoglycoside antibiotics or drugs that alter renal function.
- The incidence of serum creatinine elevations >0.5 mg/dL above pre-treatment levels was statistically higher in the full-dose aprotinin group (9.0%) compared with placebo (6.6%).
- The incidence of serum creatinine elevations >2.0mg/dL above baseline was slightly higher in the full-dose aprotinin group (1.1% vs. 0.8%).
In clinical trials Trasylol® did not increase the risk of the following perioperative events: myocardial infarction, congestive heart failure, hepatic dysfunction and mortality.
For Trasylol® contraindications, warnings and precautions see prescribing information file.
The information provided on Bayer products is
only intended for the United States audience. Regulatory requirements,
regulations, laws, and distribution of information about drug products
may vary from country to country. Product names and indications
(product uses) also may be different in different countries. The
prescribing information provided here is based on United States
labeling and may not be appropriate outside of the United States.
Top of Page | Contact
Us
Safety Info
| Prescribing
Info | Press Room
Copyright ©
Bayer HealthCare Pharmaceuticals All rights reserved.
|
